Maximum Monthly Dose of Ubrogepant
The safety of treating more than 8 migraines in a 30-day period with ubrogepant has not been established 1.
Dosing Framework
The FDA-approved labeling explicitly states this monthly limitation, which translates to a practical maximum of:
- 8 migraine attacks per month can be safely treated with ubrogepant
- Each attack can be treated with up to 200 mg per 24-hour period (initial dose of 50-100 mg, with optional second dose ≥2 hours later)
- Theoretical maximum monthly dose: 1,600 mg (8 attacks × 200 mg per attack)
Clinical Context and Rationale
This monthly limitation exists because:
- Clinical trials did not evaluate safety beyond 8 treated migraines per 30 days 1
- The restriction helps prevent medication-overuse headache, a critical concern with acute migraine treatments 2
- Patients requiring treatment for more frequent attacks should be evaluated for preventive migraine therapy 2
Important Caveats
Medication-overuse headache thresholds vary by drug class: While triptans trigger medication-overuse headache at ≥10 days per month, the threshold for gepants like ubrogepant is not definitively established 2. However, the 8-migraine-per-month safety limit provides a conservative boundary.
When patients exceed this frequency: If episodic migraines occur more frequently than 8 times monthly, or if treatment doesn't provide adequate response, addition of preventive medications is warranted rather than increasing acute treatment frequency 2.
The 2025 American College of Physicians guideline positions ubrogepant as an option for moderate to severe acute episodic migraine in patients who don't tolerate or have inadequate response to triptan plus NSAID/acetaminophen combination therapy 2. The 2024 VA/DoD guideline provides a "weak for" recommendation for ubrogepant based on its efficacy profile 3.